The board of directors (the "Board") of the Company announced that, the Company has received the Acceptance Notice () of the quality and efficacy consistency evaluation of generic drugs for chemical injection (the "Consistency Evaluation") issued by the National Medical Products Administration of the PRC (the "NMPA"). The Consistency Evaluation application for Doxorubicin Hydrochloride Liposome Injection (specifications: 10ml:20mg) (LIBOd®, ®) (the "Drug") has been accepted. Relevant information is as follows: Drug name: Doxorubicin Hydrochloride Liposome Injection, Registration type: Class 6 generic drug (2007), Application matter: Application for consistency evaluation of domestic products: supplementary application items approved by the NMPA; 1. major changes in the technical guidelines related to pharmaceutical changes of listed chemical medicines; 1.2 change the production process; 1.5 change the drug registration standard; 1.5.3 others; Acceptance No.

CYHB2250452GUO, Applicant: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Review conclusion: Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China. LIBOd® (®) from Nano- drug platform of the Company for the treatment of tumors, the first generic drug from Doxil® in China and the first generic drug of nanomedicine at home and abroad, was launched for sale in August 2009 and it obtained favorable market response and reputation.

The Drug is a new doxorubicin formula which adopts the advanced stealth liposomal encapsulation technology and has passive targeting characteristics. The Drug is a new generation of replacement for anthracycline drugs. In oncology, it has the advantages of enhancing efficacy and remarkably lowering the effects of cardiac toxicity, myelosuppression and hair-loss.

The Drug is used for the treatment of AIDS-relating Kaposi's sarcoma, breast cancer and ovarian cancer, etc.